CAMP4 Therapeutics Presents Promising Preclinical Data on CMP-002 for SYNGAP1-Related Disorder
CAMBRIDGE, Mass., May 14, 2026 – CAMP4 Therapeutics Corporation (Nasdaq: CAMP), a clinical-stage biopharmaceutical company, has announced the presentation of new and highly promising preclinical data for its lead investigational antisense oligonucleotide (ASO) therapeutic candidate, CMP-002, targeting SYNGAP1-related disorder (SRD). The data were presented at the TIDES Oligonucleotide & Peptide Therapeutics conference, a major industry event, and highlight significant advancements that could have important implications for both patients and investors.
Key Points from the Report
- Statistically Significant Efficacy in Preclinical Models: CMP-002 administration resulted in a statistically significant improvement in seizure threshold and severity in a SYNGAP1 haploinsufficient mouse model. Mice treated with CMP-002 exhibited greater resistance to chemically-induced tonic-clonic seizures and a reduction in seizure severity.
- Broad Therapeutic Potential: CMP-002 not only improved seizure phenotypes but also builds on prior evidence that the candidate can restore motor and behavioral function. This suggests the potential for broad disease-modifying benefits in SYNGAP1-related disorder.
- Clear Advancement Path: CAMP4 plans to advance CMP-002 into a Phase 1/2 clinical trial in SRD patients in the second half of 2026, marking a critical milestone for the company and the program.
- Mechanism of Action: CMP-002 is designed to bind to a SYNGAP1-specific regulatory RNA (regRNA), increasing SYNGAP1 gene expression and restoring protein levels toward normal. This approach is intended to address the underlying cause of SYNGAP1-related disorder.
- Additional Preclinical Evidence: CMP-002 has shown dose-dependent increases in SYNGAP protein expression in patient-derived neurons, reversal of disease-relevant behavioral phenotypes in a humanized mouse model, and broad brain distribution with significant protein upregulation in non-human primates.
- Unmet Medical Need: SYNGAP1-related disorder is a rare, severe CNS disorder affecting over 10,000 individuals in the U.S., characterized by intellectual disability (100%), epilepsy (~85%), severe behavioral issues (~70%), sleep problems (~60%), and limited communication abilities. There are currently no approved disease-modifying therapies for this patient population.
Potentially Price-Sensitive and Shareholder-Relevant Information
- Clinical Advancement Timeline: The company expects to initiate Phase 1/2 clinical trials for CMP-002 in the second half of 2026. Progression into human trials could be a major catalyst for the stock, as it validates the transition from preclinical to clinical development.
- First-in-Class Therapeutic Approach: CMP-002 represents a novel, RNA-targeting therapy that could be first-in-class for SRD, addressing a large unmet need in a rare disease with no current treatments. The success of CMP-002 could position CAMP4 as a leader in the field of RNA therapeutics for neurological disorders.
- Platform Potential: CAMP4’s proprietary RAP Platform® enables the mapping and targeting of regulatory RNAs across a range of haploinsufficient and recessive partial loss-of-function disorders (over 1,200 conditions). This platform approach may offer significant pipeline expansion opportunities if CMP-002 demonstrates clinical efficacy.
- Exposure to Development Risks: The company acknowledges that preclinical and clinical development is subject to significant risk, including uncertain outcomes, potential delays, manufacturing challenges, and reliance on specialized personnel. These risks could affect the timing and success of product development and commercialization.
About CAMP4 Therapeutics and CMP-002
CAMP4 Therapeutics is focused on developing disease-modifying treatments for genetic diseases by amplifying healthy protein production using antisense oligonucleotides that target regulatory RNAs. The company’s RAP Platform® is designed to identify and target the master regulators of gene expression, potentially benefiting a wide range of genetic disorders where increased protein expression is therapeutic.
CMP-002 is the company’s lead investigational ASO therapeutic, administered intrathecally, and has demonstrated promising results in preclinical models for increasing SYNGAP1 protein expression and improving disease phenotypes. The upcoming clinical trials represent a pivotal step for the program and the company.
Investor Considerations
- Pipeline Validation: Successful transition of CMP-002 into clinical development and positive readouts could significantly enhance CAMP4’s valuation and pipeline credibility.
- Orphan Drug Potential: Given the rare nature of SRD and high unmet need, CMP-002 could qualify for orphan drug status, providing regulatory and commercial advantages.
- Market Opportunity: With over 10,000 affected individuals in the U.S. and no approved therapies, the addressable market is significant for a rare disease.
- Risks: Investors should be aware of the risks associated with early-stage drug development, including the potential for setbacks in clinical trials, manufacturing, and regulatory pathways.
Contact Information
Investor Relations: Sara Michelmore, Milestone Advisors, [email protected]
Media: Sofia Bermudez, LifeSci Communications, [email protected]
Disclaimer: This article is for informational purposes only and does not constitute investment advice. All forward-looking statements are subject to risks, uncertainties, and assumptions that could cause actual results to differ materially. Investors are urged to read the company’s filings with the U.S. Securities and Exchange Commission and to consult with their financial advisors before making investment decisions.
